ASCO 2019: Form Biomarker Discovery to Photo-Immunotherapy
Jul 17, 2019 ·
41m 36s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
In this episode of the Onco’Zine Brief Peter Hofland reports from the 2019 annual meeting of the American Society of Clinical Oncology – ASCO – which was held May 31st...
show more
In this episode of the Onco’Zine Brief Peter Hofland reports from the 2019 annual meeting of the American Society of Clinical Oncology – ASCO – which was held May 31st – June 4th, 2019.
Hofland talks with:
- Dr. Hartmut Juhl, the Chief Executive Officer of Indivumed, a physician-led, integrated global oncology company. The company offers specialized products and services designed to support the discovery of biomarkers, drug development, clinical trials, and individualized treatment for patients with cancer, and
- Dr. Jeannie Hou, Vice President Clinical Development at Rakuten Medical, a company developing precision-targeted medicines through the development of a novel, proprietary photo-immunotherapy platform.
For more information, please visit Onco'Zine at www.oncozine.com
show less
Hofland talks with:
- Dr. Hartmut Juhl, the Chief Executive Officer of Indivumed, a physician-led, integrated global oncology company. The company offers specialized products and services designed to support the discovery of biomarkers, drug development, clinical trials, and individualized treatment for patients with cancer, and
- Dr. Jeannie Hou, Vice President Clinical Development at Rakuten Medical, a company developing precision-targeted medicines through the development of a novel, proprietary photo-immunotherapy platform.
For more information, please visit Onco'Zine at www.oncozine.com
Information
Author | Peter Hofland |
Organization | Peter Hofland |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company